Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?

View More View Less
  • 1 PECEM (MD/PhD), Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México;
  • 2 Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois;
  • 3 Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York;
  • 4 Departments of Neurology and
  • 5 Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois;
  • 6 Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois; and
  • 7 Departments of Systems Biology and
  • 8 Biomedical Informatics, Columbia University, New York, New York
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

If the inline PDF is not rendering correctly, you can download the PDF file here.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Adam M. Sonabend: adam.sonabend@nm.org.

INCLUDE WHEN CITING Published online December 6, 2019; DOI: 10.3171/2019.9.JNS192523.

Disclosures Dr. Lukas has received support from Roche-Genentech for meeting travel to present study results; honoraria for advisory boards for AstraZeneca, Abbvie, and Ziopharm; and honoraria for medical editing for EBSCO publishing, Medlink Neurology, and American Physician Institute. He has also received honoraria for consultation with Eisai and Abbvie, and honoraria for creating and presenting CME Board review material for the American Physician Institute. Dr. Iwamoto is a consultant for Merck, Novocure, Regeneron, Abbvie, Alexion, Guidepoint, and Tocagen. He has received clinical or research support for the study described (includes equipment or material) from Novocure, Bristol Myers Squibb, Celldex, Northwest Biotherapeutics, Stemline, Regeneron, Incyte, Immunocellular Therapeutics, Merck, and Forma. Drs. Sonabend, Iwamoto, and Rabadan are co-authors for the following patent filed by Columbia University: Systems and methods for predicting clinical responses to immunotherapies. Dr. Rabadan is a member of the SAB of AimeBio. Dr. Lukas received drug support (but no additional support) from BMS for an investigator-initiated trial.

  • 1

    Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, : Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24:16491654, 2018

    • Search Google Scholar
    • Export Citation
  • 2

    Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, : Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:28722878, 2018

    • Search Google Scholar
    • Export Citation
  • 3

    Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, : Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129:453460, 2016

    • Search Google Scholar
    • Export Citation
  • 4

    Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, : Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:22062211, 2016

    • Search Google Scholar
    • Export Citation
  • 5

    Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, : The somatic genomic landscape of glioblastoma. Cell 155:462477, 2013

    • Search Google Scholar
    • Export Citation
  • 6

    Bristol-Myers Squibb: Bristol-Myers Squibb announces Phase 3 CheckMate-498 study did not meet primary endpoint of overall survival with Opdivo (nivolumab) plus radiation in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme [press release]. May 9, 2019 (https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did) [Accessed October 9, 2019]

    • Export Citation
  • 7

    Bristol-Myers Squibb: Bristol-Myers Squibb provides update on Phase 3 Opdivo (nivolumab) CheckMate-548 trial in patients with newly diagnosed MGMT-methylated glioblastoma multiforme [press release]. September 5, 2019 (https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab-) [Accessed October 9, 2019]

    • Export Citation
  • 8

    Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, : Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477486, 2019

    • Search Google Scholar
    • Export Citation
  • 9

    De Groot JF, Penas-Prado M, Mandel JJ, O’Brien BJ, Weathers SPS, Zhou S, : Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. J Clin Oncol 36 (15 Suppl):2008, 2018 (Abstract)

    • Search Google Scholar
    • Export Citation
  • 10

    Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, : Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378:1976–1986, 2018

    • Search Google Scholar
    • Export Citation
  • 11

    Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, : Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:25982608, 2017

    • Search Google Scholar
    • Export Citation
  • 12

    Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, : Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov 6:12301236, 2016

    • Search Google Scholar
    • Export Citation
  • 13

    Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, : Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. OncoImmunology 8:e1561106, 2019

    • Search Google Scholar
    • Export Citation
  • 14

    Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, : Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565:234239, 2019

    • Search Google Scholar
    • Export Citation
  • 15

    Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, : IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 24:25592573, 2018

    • Search Google Scholar
    • Export Citation
  • 16

    Larouche V, Atkinson J, Albrecht S, Laframboise R, Jabado N, Tabori U, : Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatr Blood Cancer 65:e27389, 2018

    • Search Google Scholar
    • Export Citation
  • 17

    Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, : Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 6:13821399, 2016

    • Search Google Scholar
    • Export Citation
  • 18

    Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, : Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol 140:317328, 2018

    • Search Google Scholar
    • Export Citation
  • 19

    Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, : Clonal deletion of tumor-specific T cells by interferon-g confers therapeutic resistance to combination immune checkpoint blockade. Immunity 50:477492.e8, 2019

    • Search Google Scholar
    • Export Citation
  • 20

    Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, : Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84–88, 2007

    • Search Google Scholar
    • Export Citation
  • 21

    Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, Groot JFD, : Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol 36 (15 Suppl):2006, 2018 (Abstract)

    • Search Google Scholar
    • Export Citation
  • 22

    Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, : OS10.3. Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 19 (Suppl 3):iii21, 2017 (Abstract)

    • Search Google Scholar
    • Export Citation
  • 23

    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, : Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:18231833, 2016

    • Search Google Scholar
    • Export Citation
  • 24

    Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, : Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348:124128, 2015

    • Search Google Scholar
    • Export Citation
  • 25

    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, : Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320330, 2015

    • Search Google Scholar
    • Export Citation
  • 26

    Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, : Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202206, 2019

    • Search Google Scholar
    • Export Citation
  • 27

    Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, : Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470476, 2019

    • Search Google Scholar
    • Export Citation
  • 28

    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, : Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459466, 2009

    • Search Google Scholar
    • Export Citation
  • 29

    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987996, 2005

    • Search Google Scholar
    • Export Citation
  • 30

    Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, : Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:23062316, 2017

    • Search Google Scholar
    • Export Citation
  • 31

    Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, : Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:13731385, 2017

    • Search Google Scholar
    • Export Citation
  • 32

    Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, : Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:12831294, 2016

    • Search Google Scholar
    • Export Citation
  • 33

    Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, : Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 25:462469, 2019

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 84 84 84
Full Text Views 20 20 20
PDF Downloads 32 32 32
EPUB Downloads 0 0 0